FOLR1 and ovarian carcinoma: It was reported that a single dose of AZD5335 at 2.5 mg/kg was sufficient to provide a solid and consistent anti-tumor response in FRα-expressing ovarian cancer cell line xenografts (CDX) with a tumor growth inhibition (TGI) of 75–94% and median best tumor volume reduction of >30% in 14/17 (82%) ovarian cancer patient-derived xenografts (PDX).